A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

See attached image file Disclosures Tiede:Alnylam, Bayer, Biogen Idec, Biotest, Bristol-Myers-Squibb, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and SOBI: Consultancy; Alnylam, Bayer, Biogen Idec, Biotest, Bristol-Myers-Squibb, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and SOBI: Honoraria; Alnylam, Bayer, Biogen Idec, Biotest, Bristol-Myers-Squibb, Boehringer Ingelheim, CSL Behring, Leo Pharma, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, and SOBI: Research Funding. Goldmann:Novo Nordisk and other companies: Honoraria; Novo Nordisk and other companies: Consultancy. Miljic:Novo Nordisk: Other: Investigator fees as a participant of the clinical trial. Korsholm:Novo Nordisk A/S: Employment; Novo Nordisk A/S: Other: Owns stocks. Matytsina:Novo Nordisk A/S: Other: Owns stocks; Novo Nordisk A/S: Employment. Persson:Novo Nordisk A/S: Employment; Novo Nordisk A/S: Other: Owns stocks. Lissitchkov:Novo Nordisk: Other: Investigator fees as a participant of the clinical trial.